Symbicort Turbuhaler 60MD is a combination maintenance inhaler designed for the long-term management of asthma and chronic obstructive pulmonary disease (COPD). It integrates an inhaled corticosteroid (budesonide) and a long-acting beta2-agonist (formoterol) in a single, easy-to-use dry powder inhaler device. This formulation provides both anti-inflammatory and bronchodilatory effects, aimed at improving lung function, reducing exacerbation frequency, and enhancing overall respiratory control. It is intended for regular use and should be prescribed following a thorough clinical assessment.

Features

• Contains budesonide 160 mcg and formoterol fumarate dihydrate 4.5 mcg per inhalation
• Delivered via the Turbuhaler® dry powder inhaler device
• Multidose inhaler with 60 metered doses
• Does not require shaking or coordination of actuation with inhalation
• Dose counter to track remaining medication
• Breath-actuated mechanism for efficient drug delivery to the lungs

Benefits

• Provides dual-action therapy combining anti-inflammatory and bronchodilator effects
• Reduces the frequency and severity of asthma and COPD exacerbations
• Improves lung function and symptom control with consistent use
• Offers convenience through a single-inhaler maintenance regimen
• Features a dose indicator to help monitor adherence and remaining supply
• Designed for patient-friendly administration with minimal preparation steps

Common use

Symbicort Turbuhaler 60MD is indicated for the maintenance treatment of asthma in patients aged 18 years and older where a combination therapy is appropriate. It is also approved for the symptomatic treatment of patients with severe COPD (FEV₁ < 50% predicted normal) and a history of repeated exacerbations, who have significant symptoms despite regular bronchodilator therapy. It is not intended for the relief of acute bronchospasm.

Dosage and direction

For asthma: The recommended dose is 1 or 2 inhalations twice daily. The maximum recommended dose is 4 inhalations twice daily. For COPD: The recommended dose is 2 inhalations twice daily. Always follow the prescribing physician’s instructions. To use, hold the Turbuhaler upright, load a dose by twisting the grip fully in one direction and back, exhale away from the mouthpiece, place lips firmly around it, and inhale deeply and forcefully. Remove the inhaler and hold breath for about 10 seconds if possible. Rinse mouth with water after use to reduce the risk of oral candidiasis.

Precautions

• Not for relief of acute symptoms; a separate fast-acting inhaler should be prescribed for rescue use.
• Caution in patients with tuberculosis, fungal, bacterial, or viral infections, or untreated systemic infections.
• Use with caution in patients with cardiovascular disorders, diabetes, hypokalemia, or thyrotoxicosis.
• Monitor growth in children and adolescents on prolonged corticosteroid therapy.
• Risk of systemic corticosteroid effects such as adrenal suppression with high doses over time.
• May cause paradoxical bronchospasm; discontinue immediately if it occurs.

Contraindications

• Hypersensitivity to budesonide, formoterol, or any ingredient in the formulation.
• Primary treatment of status asthmaticus or other acute episodes of asthma or COPD where intensive measures are required.

Possible side effects

Common side effects may include:

• Headache
• Oropharyngeal candidiasis (thrush)
• Hoarseness or dysphonia
• Cough
• Tremor
• Palpitations

Less common but serious side effects may include:

• Increased risk of pneumonia (particularly in COPD patients)
• Cardiovascular effects (tachycardia, arrhythmias)
• Systemic corticosteroid effects (e.g., adrenal insufficiency, reduced bone density)
• Hypersensitivity reactions
• Paradoxical bronchospasm

Drug interaction

• Concomitant use with other beta-adrenergic drugs may potentiate sympathetic effects.
• Ketoconazole, itraconazole, or other potent CYP3A4 inhibitors may increase budesonide exposure.
• MAO inhibitors, tricyclic antidepressants, and QTc-prolonging agents may enhance cardiovascular effects.
• Use caution with diuretics or xanthine derivatives due to potential hypokalemia or arrhythmias.

Missed dose

If a dose is missed, take it as soon as remembered unless it is nearly time for the next dose. Do not double the dose to make up for a missed one. Resume the regular dosing schedule.

Overdose

Overdosage may lead to exaggerated pharmacologic effects such as tachycardia, tremor, headache, nausea, and hypokalemia. Cardiac arrhythmias or angina may occur. Supportive and symptomatic treatment is recommended. Consider cardioselective beta-blockers with caution in patients with bronchospastic disease.

Storage

Store at room temperature (15–30°C) in a dry place. Keep the lid tightly closed when not in use. Do not expose to moisture or store in humid environments. Discard the inhaler when the dose counter shows zero, or 3 months after removal from the foil pouch, whichever comes first. Keep out of reach of children.

Disclaimer

This information is for educational purposes and does not replace professional medical advice. Always consult a healthcare provider for diagnosis, treatment decisions, and personalized guidance. Do not initiate or discontinue medication without consulting a physician.

Reviews

Symbicort Turbuhaler is widely regarded in clinical practice for its efficacy in improving symptom control and quality of life in asthma and COPD patients. Many users report reduced exacerbation rates and improved exercise tolerance. Some note the convenience of a combined agent and the ease of use of the Turbuhaler device. A minority of users report side effects such as oral thrush or hoarseness, though these are often manageable with proper technique and oral hygiene. Adherence to prescribed dosing and regular follow-up are emphasized for optimal outcomes.